Invention Application
- Patent Title: PEPTIDE FOR TREATING INFLAMMATION AND WOUNDS
-
Application No.: US17718758Application Date: 2022-04-12
-
Publication No.: US20220242904A1Publication Date: 2022-08-04
- Inventor: Yoon Jeong Park , Chong-Pyoung Chung , Jue-Yeon Lee
- Applicant: NIBEC CO., LTD. , SEOUL NATIONAL UNIVERSITY R&B FOUNDATION
- Applicant Address: KR Chungcheongbuk-do; KR Seoul
- Assignee: NIBEC CO., LTD.,SEOUL NATIONAL UNIVERSITY R&B FOUNDATION
- Current Assignee: NIBEC CO., LTD.,SEOUL NATIONAL UNIVERSITY R&B FOUNDATION
- Current Assignee Address: KR Chungcheongbuk-do; KR Seoul
- Priority: KR10-2019-0145025 20191113
- Main IPC: C07K2/00
- IPC: C07K2/00 ; A61P29/00 ; A61P37/06 ; A61P19/02 ; A61P1/04 ; A61P17/06 ; A61P17/02

Abstract:
The present invention relates to a peptide for treating inflammation and wounds and, more specifically, to use of a peptide for treating inflammation and wounds, wherein the peptide binds to collagen type VII exposed by damage to tissue and recognizes collagen type VII as an antigen, thereby inhibiting the induction of an immune response, and thus having a function of inhibiting inflammation caused by an autoimmune response, and has the function of promoting wound healing by promoting cell proliferation and migration to a wound site in the damaged tissue. The peptide according to the present invention has the binding ability to collagen type VII, and thus inhibits an immune response caused by collagen type VII, thereby inhibiting inflammation caused by an autoimmune response. In addition, the peptide can bind to the integrin beta 1 of intestinal epithelial cells and increase the cell adhesion and migration via phosphor-FAK signal and tight junction markers are increased via FAK-RhoA signal and thus promote intestine regeneration.
Information query